• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dawn Holcombe Addresses the Continuing Challenges of Defining Evidence and Value in Oncology

Article

Dawn Holcombe, President of DGH Consulting and Executive Director of the Connecticut Oncology Association, discusses how the increasing demand for data and defining evidence and value are so complex that collaboration between payers and providers is critical.

She also addresses her concern for the viability of the oncology market given the uncertainties of additional changes the federal government may make—especially in an election year—and how such changes could negatively impact the delivery of cancer care.

Related Videos
Craig A. Portell, MD, UVA Health
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Dr Johnie Rose
Andrew Kuykendall, MD
Joseph Saseen, PharmD
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Carla Nester, MD, MSA, FASN
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.